Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications

BACKGROUND: Entrectinib is a tropomyosin receptor kinase inhibitor approved for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours based on single-arm trials. Traditional randomised clinical trials in rare cancers are not feasible; we conducted an intrapatien...

Descripción completa

Detalles Bibliográficos
Autores principales: Krebs, M.G., Blay, J.-Y., Le Tourneau, C., Hong, D., Veronese, L., Antoniou, M., Bennett, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103537/
https://www.ncbi.nlm.nih.gov/pubmed/33676294
http://dx.doi.org/10.1016/j.esmoop.2021.100072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103537/
https://www.ncbi.nlm.nih.gov/pubmed/33676294
http://dx.doi.org/10.1016/j.esmoop.2021.100072

Ejemplares similares